RxDoctor Payments Data

Megan Baumgart, MD

Medical Oncology · Rochester, NYNPI 1881896157

Payments from drug & device makers

$530,971in general payments, 2019–2025

Across 45 payments — averaging $11,799 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$384K
  • Pfizer$124K
  • Iovance Biotherapeutics, Inc.$10K
  • Astrazeneca UK Limited$7K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Beigene, Ltd.$2K
  • plus $164 from 2 others

What the payments were for

  • Consulting fees$5,03785%
  • Travel & lodging$63011%
  • Food & beverage$1703%
  • Education$571%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$530,971 in reported general payments places this provider in the 60th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York

Medicare billing

Part B allowed, 2024
$33,281
Medicare patients
91
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prochlorperazine Maleate63$826
Dexamethasone19$278
Ondansetron Hcl51$199
Levothyroxine Sodium32$149
Gabapentin19$107
Oxycodone Hcl21$100
Prednisone13$85

Paid to pharmacies, not to this prescriber.

Other medical oncology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →